Bosentan is a dual endothelin receptor antagonist used in the treatment of
pulmonary artery hypertension (PAH). It is licensed in the United States, the
Tracleer(R) (bosentan) for Pulmonary Arterial Hypertension - Find information
about TRACLEER. Learn about the TRACLEER REMS (Risk Evaluation and
Jul 15, 2016 ... Bosentan: learn about side effects, dosage, special precautions, and more on
Tracleer (bosentan) 62.5mg film-coated tablets - Summary of Product
Characteristics (SPC) by Actelion Pharmaceuticals UK Ltd.
Pulmonary arterial hypertension (PAH) can be treated by Bosentan tablets such
as Tracleer. More about Bosentan tablets.
Bosentan for treatment of inoperable chronic thromboembolic pulmonary
hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc ...
Consumer information about the medication BOSENTAN - ORAL (Tracleer),
includes side effects, drug interactions, recommended dosages, and storage ...
Jun 13, 2005 ... Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9
and CYP3A4 (and possibly CYP2C19), producing three ...
WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY.
Because of the risks of hepatotoxicity and birth defects, Tracleer is available only
Bosentan is a dual endothelin receptor antagonist important in the treatment of
pulmonary artery hypertension (PAH). It is licensed in the United States, the ...